You are here:

rituximab (MabThera)


Following a full submission

rituximab (MabThera) is accepted for restricted use within NHS Scotland for first-line treatment of patients with chronic lymphocytic leukaemia (CLL) in combination with fludarabine and cyclophosphamide.

Rituximab in combination with fludarabine and cyclophosphamide resulted in significantly longer progression free survival than fludarabine and cyclophosphamide alone. The patient population in the pivotal clinical study had an Eastern Cooperative Oncology Group Performance Status of 0 or 1 and was a younger population than that generally seen in practice. Evidence in patients over 70 years of age is limited.

Rituximab is restricted to use by specialists in haematology and haemato-oncology

Drug Details

Drug Name: rituximab (MabThera)
SMC Drug ID: 540/09
Manufacturer: Roche
Indication: Chronic Lymphocytic Leukaemia (CLL)
BNF Category:
Submission Type: Full submission
Status: Restricted
Date Advice Published: 8 June 2009